Business Overview - United Therapeutics focuses on developing novel, life-extending technologies for patients in oncology, lung disease, and organ manufacturing[8] - The company has multiple approved therapies and over 20 years of experience addressing unmet medical needs in pulmonary arterial hypertension (PAH) and neuroblastoma (NB)[9] - United Therapeutics aims to find a cure through balance and value creation[11] Financial Performance & Product Strategy - Treprostinil revenue remains stable despite generic competition[13] - United Therapeutics believes Remodulin revenues will continue to grow due to safety, supply chain reliability, patient support, a highly differentiated product platform, and limited switching in the PAH space[17, 18, 19] - The company aims to expand its reach to 25,000 patients on PH therapies, a 3x increase from the current 7,500 patients[31, 32] Pipeline Development - Key benefits of expanded Orenitram label include a 61% reduction in risk of disease progression, improvement in key prognostic measures, a 37% reduction in risk of death, and reduced PAH-associated healthcare costs relative to selexipag[36] - Tyvaso increased the six-minute-walk-distance (6MWD) by 21 meters versus placebo (p=00043) after 16 weeks of treatment in PH WHO Group 3 patients[43] - The company is developing a pump for every PAH patient, including an implantable system for Remodulin (ISR) and Remunity[48, 49] Organ Manufacturing - United Therapeutics aims to transform the marketplace to make more organs available for transplant through EVLP, XENO, Lung Lobes, and 3DAP technologies[61] - In organ manufacturing, 152 EVLP patients' lives have been saved, Xeno kidneys have supported life for >6 months in preclinical models, Lung Lobes have achieved 70% recellularization and 15% lung function, and 60% of lungs have been 3DAP printed[64]

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2020 Earnings Conference Call July 29, 2020 9:00 AM ET Corporate Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairman and Chief Operating Officer Mike Benkowitz - President and Chief Operating Officer Leigh Peterson - Vice President, Product Development Conference Call participants Hartaj Singh - Oppenheimer Eun Yang - Jefferies Martin Auster - Credit Suisse Liana Moussatos - Wedbush Securities Christopher Zopf - Cowen and Compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) | Delaware | | --- ...

Financial Performance & Strategy - United Therapeutics' treprostinil revenue remains stable despite generic competition[22] - The company believes Remodulin revenues will continue to grow due to safety, supply chain reliability, patient support, and a highly differentiated product platform[27, 28] Pulmonary Hypertension (PH) Market & Opportunities - United Therapeutics is targeting expansion in the PH market, including PH associated with Interstitial Lung Disease (ILD) and Chronic Obstructive Pulmonary Disease (COPD)[32] - The company estimates over 130,000 patients in the U S have PH ILD and ~100,000 have PH COPD[36] - United Therapeutics aims to reach 25,000 patients on PH therapies, a 3x increase from the current 7,500 patients[40, 41] Orenitram® Label Expansion Benefits - Expanded Orenitram® label shows a 61% reduction in the risk of disease progression[45] - Orenitram® is associated with a 37% reduction in the risk of death versus placebo at study closure[45] - PAH-related healthcare costs were 67% higher for selexipag patients than for Orenitram patients[45] Pipeline Development & Milestones - Tyvaso® INCREASE Phase III clinical trial in PH WHO Group 3 hit primary and all secondary endpoints, with sNDA planned mid-2020[49, 51] - Tyvaso increased six-minute-walk-distance (6MWD) by 21 meters versus placebo after 16 weeks of treatment (p=0 0043)[53] - Implantable System for Remodulin® is FDA cleared with U S launch targeted for July 2020[59, 87] Organ Manufacturing - United Therapeutics is developing organ manufacturing technologies, including EVLP, XENO kidneys, lung lobes, and 3DAP lungs[73] - EVLP has saved the lives of 137 patients[75] - 60% of lung 3DAP has been printed[75]

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2020 Earnings Conference Call April 29, 2020 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairman & CEO Michael Benkowitz - President & COO Leigh Peterson - VP, Product Development James Edgemond - CFO & Treasurer Conference Call Participants Chris Shibutani - Cowen Eun Yang - Jefferies Hartaj Singh - Oppenheimer Jessica Fye - JPMorgan Liana Moussatos - Wedbush Securities Martin Auster - Credit Suisse Operator Good morning, a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2019 Earnings Conference Call February 26, 2020 9:00 AM ET Company Participants Dewey Steadman - Head of IR James Edgemond - CFO and Treasurer Martine Rothblatt - Chairman and CEO Michael Benkowitz - President and COO Leigh Peterson - VP, Product Development Conference Call Participants Chris Shibutani - Cowen Liana Moussatos - Wedbush Securities Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer Thomas Deal - Credit Suisse Eun Yang - Jefferies Geoff Meacham - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Oth ...

UNITED THERAPEUTICS CORPORATION J.P. Morgan Healthcare Conference January 13, 2020 SAFE HARBOR STATEMENT | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2019 Earnings Conference Call October 30, 2019 9:00 AM ET Company Participants James C. Edgemond - CFO & Treasurer Dr. Martine A. Rothblatt - Chairman and CEO Michael I. Benkowitz - President and COO Conference Call Participants Jessica Fye - JP Morgan Martin Auster - Credit Suisse Liana Moussatos - Wedbush Securities Hartaj Singh - Oppenheimer & Company Operator Good morning and welcome to the United Therapeutics Corporation Third Quarter 2019 Earnings Call. ...